The anti-MAGED1 Ctr Antibody is used in Western blot to detect MAGED1 in A549 lysate.
MAGED1 / NRAGE Antibody (aa426-456)
Primary AntibodyLSBio Guarantee
| Antibody: | Rabbit Polyclonal |
| Applications: | Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot |
| Reactivity: | Human |
| Format: | Liquid |
$401.00each
Catalog Number: LS-C100414-400
Catalog Number: LS-C100414
For bulk orders or custom formulations:
Request a QuoteOverview
- Description
- NRAGE antibody LS-C100414 is an unconjugated rabbit polyclonal antibody to human NRAGE (MAGED1) (aa426-456). Validated for IHC and WB. Cited in 1 publication.
- Application
- IHC, IHC-P, WB
- Reactivity
- Hu
- Predicted Reactivity
- Pig
- Intended Use
- Research Use Only
- Guarantees
- This antibody carries the LSBio 100% Guarantee. ✓
- Category
- Antibodies > Primary Antibodies > Polyclonal Antibodies
- Alternative Names
- DLXIN-1 | MAGE-D1 antigen | Melanoma antigen family D, 1 | NRAGE | MAGE tumor antigen CCF | MAGED1 | Melanoma-associated antigen D1
- Recommended Dilution: IHC-P
- 1:50 - 1:100
- Recommended Dilution: WB
- 1:1000
- NCBI GenBank
- NM_006986 | NP_008917.3
Target
- Target
- Human MAGED1 / NRAGE
- Antigen Species
- Human
- Epitope
- This MAGED1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 426-456 amino acids from the Central region of human MAGED1.
Antibody
- Host Species
- Rabbit
- Clonality
- Polyclonal
Immunogen
- Immunogen Type
- Peptide
Format
- Conjugate/Label
- Unconjugated
- Format
- Liquid
- Formulation
- PBS, 0.09% Sodium Azide
- Volume
- 400 Microliter
- Preservative
- Yes
- Purification Method
- Ammonium Sulfate Precipitation
Storage & Handling
- Storage Conditions
- Maintain refrigerated at 2°C to 8°C for up to 6 months. For long term storage store at -20°C.
- Recommended Storage Buffer
- PBS
NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, Tanaka C, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. Oncology letters. 2016;11:1847-1854. PubMed: 26998088 PMC: PMC4774420